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Cellular differentiation is regulated on the level of gene expression, and it is known that
dysregulation of gene expression can lead to deficiencies in differentiation that contribute
to a variety of diseases, particularly of the immune system. Until recently, it was thought
that the dysregulation was governed by changes in the binding or activity of a class of
proteins called transcription factors. However, the discovery of micro-RNAs and recent
descriptions of long non-coding RNAs (lncRNAs) have given enormous momentum to a
whole new field of biology: the regulatory RNAs. In this review, we describe these two
classes of regulatory RNAs and summarize what is known about how they regulate aspects
of the adaptive and innate immune systems. Finally, we describe what is known about the
involvement of micro-RNAs and lncRNAs in three different autoimmune diseases (celiac
disease, inflammatory bowel disease, and multiple sclerosis).
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INTRODUCTION
The discovery of the first micro-RNA (miRNA) in 1993 (1, 2)
was the start of research that has led to the understanding that
gene regulation is not only controlled by proteins (transcription
factors) but also RNA molecules. Since then, thousands of novel
non-coding RNAs, which can be subdivided into dozens of fam-
ilies (3), have been identified. Two of the most widely studied
classes of non-coding RNAs, miRNAs and long non-coding RNAs
(lncRNAs), are now recognized as important regulators of gene
expression. These molecules are also designated as (small or long)
regulatory RNAs. At the time of writing this review, the authora-
tive miRNA database miRBase (release 21) describes 1,881 human
miRNA precursors and 2,588 human mature miRNA sequences
Abbreviations: 3′-UTR, 3′-untranslated region; Aicda, activation-induced cyti-
dine deaminase; BACE1, gene encoding β-secretase-1; AGO, Argonaute; AP-1,
activator protein-1; APAF1, apoptotic protease activating factor 1; APC, antigen-
presenting cell; Bak1, Bcl-2 homologus antagonist/killer 1; BBB, blood–brain bar-
rier; Bcl-2, B-cell lymphoma-2; BDNF, brain-derived neurothrophic factor; Bim,
pro-apoptotic factor; BLIMP-1, B lymphocyte-induced maturation protein-1; BM,
bone marrow; CaMKII, calcium/calmodulin-dependent protein kinase II; Cepba,
CCAAT/enhancer binding protein-α; CCL1, chemokine (C-C motif) ligand 1; CD,
Crohn’s disease; CDK, cyclin-dependent kinase; CeD, celiac disease; C-ETS, c-E26
transformation specific transcription factor; CLP, common lymphoid progenitor;
CMP, common myeloid progenitor; CRC, colorectal carcinoma; CREB, cyclic AMP-
responsive element binding protein; CSF, cerebrospinal fluid; CSF1, colony stimu-
lating factor 1; CXCL10, C-X-C motif chemokine 10; DC, dendritic cell; DGCR8,
DiGeorge syndrome critical region gene 8; DN, double negative; DOCK-1, dedicator
of cytokinesis-1; DP, double positive (CD4+CD8+); DSS, dextran sulfate sodium;
EAE, autoimmune encephalomyelitis; EBV, Epstein–Barr virus; eQTL, expression
quantitative trait locus; FADD, Fas-associated death domain; Fo, follicular B-cell;
Foxp3, forkhead box P3; GC, germinal center; GWAS, genome-wide association
study; hnRNP, heterogeneous nuclear ribonucleoprotein; HOX, homeobox; HSC,
hematopoietic stem cell; IBD, inflammatory bowel disease; IFN, interferon; IGF-
1, insulin-like growth factor 1; Ikzf4, Ikaros family zinc finger 4; IL, interleukin;
IPA, ingenuity pathway analysis; IRAK1, interleukin-1 receptor-associated kinase 1;
IRF4, IFN regulatory factor 4; IRS-1, insulin regulatory subunit-1; iTreg, induced
regulatory T-cell; JNK, JUN N-terminal kinase; KO, knockout; lincRNA, long
(4), whereas the GENCODE compendium (V19) mentions 13,870
human lncRNA genes (5). MiRNAs are thought to affect gene
expression by inhibiting target mRNA translation (which leads
indirectly to degradation of the target) or they can directly induce
target mRNA degradation. Many lncRNAs are thought to be
involved in chromatin modification processes that, in turn, affect
gene expression levels (Figure 1). The role of miRNAs in home-
ostasis and the deregulation of miRNAs in human disease have
been well established, but the role of lncRNAs in these processes
is not yet fully appreciated. Here, we will review what is known
about the role of miRNAs and lncRNAs in the development and
activation of the adaptive and innate immune systems in health
and disease.
intergenic ncRNA; LLRK2, leucine-rich repeat kinase-2; lncRNA, long non-coding
RNA; LPS, lipopolysaccharide; Lt-α, lymphotoxin-α; MAPK, mitogen-activated
protein kinase; MBP, oligodendrogial myelin basic protein; MEK, MAPK kinase;
miRNA, micro-RNA; mirtron, intron-derived splicing-dependent miRNA; MS,
multiple sclerosis; mTOR, mammalian target of rapamycin; MZ, marginal zone;
MZF-1, myeloid zinc finger-1; NATs, natural antisense transcripts; ncRNA, non-
coding RNA; NEAT1, nuclear enriched abundant transcript 1; NF-κB, nuclear
factor-κB; NK, natural killer; PBMC, peripheral blood mononuclear cell; Phlpp2, PH
domain and leucine-rich repeat protein phosphatase 2; PI3K, phosphoinositide 3-
kinase; PP-MS, primary-progressive multiple sclerosis; PMN, polymorphonuclear
cells; PRDM1, PR domain zinc finger protein 1; pre-miRNA, precursor-miRNA;
pri-miRNA, primary miRNA; PTEN, phosphatase and tensin homolog; RISC, RNA-
induced silencing complex; RR-MS, relapsing-remitting multiple sclerosis; RUNX-1,
runt-related transcription factor 1; siRNA, small interference RNA; SFPQ, splicing
factor proline/glutamine-rich; SOCS1, suppressor of cytokine signaling-1; simtron,
intron-derived splicing-independent miRNA; sncRNA715, small non-coding RNA
715; SNP, single nucleotide polymorphism; SOD2, superoxide dismutase 2; SP-MS,
secondary progressive multiple sclerosis; STAT, signal transducer and activator of
transcription; T-bet, T-box expressed in T-cells; TCR, T-cell receptor; TGFβ, trans-
forming growth factor β; TGFβR, TGFβ-receptor; Th, T helper; THRIL, TNFα-
and hnRNPL-related immunoregulatory lincRNA; TLR, Toll-like receptor; TNF,
tumor necrosis factor; TRAF, TNF receptor-associated factor; Treg, regulatory
T-cell; UC, ulcerative colitis; VE-cadherin, vascular endothelial-cadherin; XPO5,
exportin 5.
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FIGURE 1 | Multiple layers of gene expression controlled by
transcription factors, miRNAs, and lncRNAs. (A) Protein-coding genes
are transcribed into mRNA, which subsequently are translated into
proteins. These proteins can function as the classical transcription factors.
(B) There is a second class of RNAs that is not translated into protein but
rather is regulating the expression of other transcripts. The third class of
transcripts described in this review (C) is the long non-coding RNAs that
can regulate gene expression as well, although other functions for these
transcripts have been described (see Figure 3). It is becoming clear that
there is interaction within each class, but also between these three classes,
which can converge on transcriptional outcome (see text for details).
MiRNAs
Micro-RNAs are short (19–24 nt), single-stranded, RNAs that are
involved in the post-transcriptional regulation of gene expres-
sion. Their sequences are evolutionary strongly conserved. miRNA
expression profiles and target mRNA sites are also conserved,
allowing the translation of findings in mouse models to human
physiology.
Micro-RNAs are transcribed by RNA polymerase II into longer
(several hundred to several thousand nucleotides) primary miR-
NAs (pri-miRNAs), containing a cap as well as a poly-A tail. The
pri-miRNA is processed in the nucleus by a microprocessor, a com-
plex composed of Drosha (a class III RNase) and the DiGeorge
syndrome critical region gene 8 (DGCR8), into a ~60 nt precursor-
miRNA (pre-miRNA). In this step, the double-stranded stem-loop
structures are specifically recognized by the microprocessor, which
catalyzes the cleavage of the pri-miRNA near the base of the stem
(6, 7). Then, the double-stranded pre-miRNA stem-loop struc-
ture is transported into the cytoplasm by a complex containing
exportin 5 (XPO5), where it is recognized and further processed by
a class III RNase named Dicer into a double-stranded RNA duplex
of ~19–24 nt in length. Next, only one of the strands is incorpo-
rated into the RNA-induced silencing complex (RISC) composed
of Argonaute (AGO) and GW182. The RISC complex is guided to
the 3′-untranslated region (3′-UTR) of target mRNA molecules.
This leads successively to a decrease in target stability, resulting
in accelerated uncapping and deadenylation (8) and/or inhibi-
tion of translation (9) (Figure 2). It has been suggested that the
translational repression of mRNAs takes place in specialized com-
partments called processing bodies (P-bodies), compartments in
the cytoplasm involved in the storage,and degradation of repressed
mRNAs (10). To make things more complex, miRNAs were shown
to be transported to the nucleus, where they can affect their own
expression or the expression of other miRNAs (11). Moreover,
lncRNAs can act as sponges for miRNAs. It was demonstrated that
the lncRNA phosphatase and tensin homolog (PTEN) pseudo-
gene1 (PTENpg1) sequesters various PTEN -targeting miRNAs,
thereby indirectly regulating the PTEN mRNA level (12).
Reports describing that miRNAs can originate from other
regulatory RNAs, like tRNAs (13) or pre-ribosomal RNAs (14),
complicate the “canonical pathway of miRNA production.” MiR-
NAs can also be derived from introns, which mimic the structural
features of pre-miRNAs and these miRNAs can, therefore, enter
the miRNA processing pathway independent of Drosha (15). This
group of miRNAs can even be subdivided into two groups: (a)
splicing-dependent miRNAs (mirtrons, e.g., human miR-877 and
miR-1226) or (b) splicing-independent simtrons (human miR-
1225 and miR-1228). The processing of mirtrons requires the
spliceosome but not Drosha or DGCR8, whereas the generation
of simtrons depends on Drosha (but not on DGCR8). Mirtrons
are exported from the nucleus by XPO5, cleaved by Dicer, and
subsequently enter the RISC complex, similarly to canonical miR-
NAs. We do not yet know what factors regulate simtron export
from the nucleus, but simtrons also enter the RISC complex in the
cytoplasm (16).
Interest in miRNAs grew when it was found that miRNAs can
be detected in many body fluids such as serum, cerebrospinal
fluid (CSF), saliva, and urine (17) and that miRNA profiles are
remarkably stable (e.g., resistant to RNases, freeze-thaw cycles).
This protection from degradation is probably conferred by one
or more mechanisms: (1) miRNAs can be bound to protein com-
ponents of the RISC complex (AGO2), (2) they can be bound to
high density lipoproteins, or (3) they can be packaged in exosomes
(18). It was exciting to discover that miRNA profiles in circulation
can be disease or even disease stage specific (19). Moreover, they
can be useful in predicting treatment response (20). Research into
the biological role of circulating miRNAs is still in its infancy, but
recent papers describe the intriguing possibility that miRNA can
be secreted by one cell type and can then exert its function on or in
other cell types (21–23). Exosomes have been shown to participate
in various processes that are crucial for immune system function
and they can be released by various immune cell types, e.g., T-cells,
B-cells, and dendritic cells (DCs). Importantly, these exosomes
contain miRNAs, some of which are cell-type specific, while oth-
ers are present in exosomes of various cell types. Moreover, some
miRNAs are more highly expressed in exosomes than in the cells
that excrete them, implying that a subset of miRNAs is specifi-
cally packaged (24). The selection of miRNA for packaging into
exosomes has been described based on two specific motifs in the
miRNA sequence; these are recognized by sumoylated heteroge-
neous nuclear ribonucleoprotein A2/B1 (hnRNPA2B1), a protein
controlling miRNA loading into exosomes (25).
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FIGURE 2 | Biogenesis of miRNAs. MiRNAs are transcribed by RNA pol II
in the nucleus. Double-stranded miRNA hairpins in the pri-miRNA transcript
are recognized and cleaved by the microprocessor complex, composed of
Drosha and DGCR8, producing the pre-miRNA. These are subsequently
exported into the cytoplasm by XPO5, where they are recognized by Dicer,
which cuts off the loop of the hairpin yielding a small double-stranded RNA
molecule. One of these strands, the mature miRNA, is loaded into the RISC
complex that contains AGO2. This complex is guided to the target mRNA,
based on sequence homology between the miRNA and the target.
Ultimately, this leads to diminished mRNA translation and/or degradation of
the target.
LONG NON-CODING RNAs
Long non-coding RNAs are a heterogeneous group of non-coding
transcripts longer than 200 nucleotides (26, 27) and they constitute
the major class of regulatory RNA genes (28, 29). Thousands of
mammalian lncRNAs have been identified since the first genome-
wide discovery studies in the early 2000s and it has become clear
that they play important roles in regulating several biological
processes, such as gene expression, chromatin remodeling, and
protein transport. Although many lncRNAs have been identi-
fied, little is known about either their general characteristics or
their possible mechanisms of action in health and disease. They
can be detected both in the nucleus and in the cytosol, and can
be polyadenylated or not. Compared to protein-coding genes,
lncRNAs have fewer but longer exons, which are poorly conserved
across species (26, 30). In general, the expression of lncRNAs is
lower than that of protein-coding genes, although in a cell-type-
specific context the expression can be just as high (26). There is
growing evidence pointing to changes in lncRNA expression being
associated with the etiopathology of diseases, for instance in cancer
and autoimmune disease (18, 31). Expression profiling of specific
immune cell subsets has revealed an enrichment of long inter-
genic non-coding RNAs (lincRNAs) that are expressed in immune
cells in autoimmune disease-associated loci, thereby implying that
these non-coding RNAs play a role in the etiology of autoim-
mune disease (Barbara Hrdlickova, personal communication).
Furthermore, expression quantitative trait locus (eQTL) analysis
has demonstrated that disease-associated single nucleotide poly-
morphisms (SNPs) can affect the expression of lncRNAs, relating
lncRNAs to disease susceptibility (32).
Long non-coding RNAs are a structurally and functionally het-
erogeneous group of transcripts. One approach classifies them
into four different subclasses based on their location with respect
to the closest protein-coding gene (5, 18). The largest subclass
consists of the lincRNAs, which do not overlap with protein-
coding genes. Of the remaining “genic” lncRNAs (the second
largest subclass), the antisense lncRNA group contains tran-
scripts that overlap with exons of protein-coding genes on the
opposite strand (natural antisense transcripts, or NATs) or tran-
scripts that reside in an intron of the protein-coding gene on
the opposite strand (antisense intronic transcripts). The anti-
sense and sense transcripts are often co-expressed. The third
subclass of lncRNAs encompasses the sense lncRNAs. These tran-
scripts can contain coding genes within an intron on the same
strand (sense overlapping transcripts), or they can be located
within an intron of a protein-coding gene on the same strand
(sense intronic transcripts). The fourth subclass comprises the
bi-directional or divergent lncRNA transcripts. These are anti-
sense transcripts that co-transcribe in the opposite direction to
the protein-coding gene.
The GENCODE (V7) compendium has annotated over 13,000
human lncRNAs, of which only a fraction, however, has a known
function (26). LncRNAs can have diverse molecular functions
relayed by the molecules they interact with: mRNA, protein,
miRNAs, or DNA (Figure 3) (33). These interactions can affect
processes like transcription, translation, splicing, translation, or
RNA degradation (34, 35). Chang and Rinn classified lncRNAs
into four subclasses by their different functions (34). For exam-
ple, lncRNAs can function as molecular scaffolds to bring proteins
together in a complex, but they can also act as a signal for a spe-
cific biological condition or state, for instance cellular stress or
temperature. The signal can subsequently activate or repress the
expression of other genes. Another function lncRNAs can exhibit
is that of being a decoy, in which they bind to other RNAs or pro-
teins and interfere with their function. Finally, lncRNAs can guide
protein complexes to targets, where they can act as activators or
repressors of other genes. In addition to these four main func-
tions, some lncRNAs can inhibit the function of miRNAs, thereby
alleviating the downregulating effect of the miRNA on the gene
expression (36–38). Note that it is also possible for lncRNAs to
exert multiple of these functions.
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FIGURE 3 | Molecular functions of lncRNAs. (A) LncRNAs can act as
signaling molecules, affecting the expression of genes in response to a
stimulus. (B) LncRNAs can divert transcription factors or other proteins
away from the DNA. (C) Other lncRNAs can recruit proteins, bringing them
closer to target genes. (D) As scaffolds, lncRNAs can bring together
multiple proteins to form complexes.
THE ROLE OF miRNAs AND lncRNAs IN THE IMMUNE
SYSTEM
It has been proposed that miRNA emerged as a primitive immune
response against viral infection. The fact that they show remark-
able conservation in animals and plants suggests they hold impor-
tant biological functions. MiRNAs play important roles in cell
physiology, as clearly demonstrated by the fact that Dicer knock-
out in mouse embryos is incompatible with life. Deleting or
overexpressing individual miRNAs in mice offers the opportu-
nity to study their roles in the immune response (39). Lineage-
specific knockout (KO) of miRNAs in specific immune cell types
results in severe perturbation of immune cell numbers, their
composition, and function. These all points to miRNAs being
essential for immune cell development, differentiation, function,
and homeostasis (39–43).
Dicer1 deletion in granulocyte-macrophage progenitors
(derived from a myeloid-specific CCAAT/enhancer binding
protein-α (Cebpa)-Cre-driven Dicer1-deleter mouse strain)
resulted in changes in gene expression profiles, increased self-
renewal ability of precursors in the bone marrow (BM), monocyte
depletion, and myeloid dysplasia, underlining the essential contri-
bution of miRNAs to myeloid development (44). The role of Dicer
and miRNAs has also been demonstrated in natural killer (NK)
cells. By using mice with conditional deletion of Dicer1 or Dgcr8
in NK cells, a reduced cellularity in the spleen was observed with
a concomitant reduced frequency of splenic NK cells, but without
alterations in T- and B-cell frequencies. Dicer and Dgcr8 deficiency
was associated with an increase in NK apoptosis and an impair-
ment in NK activation, suggesting that miRNAs are required for
NK homeostasis and function (45).
As discussed above, miRNAs can be packaged into exosomes
that are subsequently secreted from the cell. It has been suggested
that circulating miRNAs could act in intercellular communica-
tion, also in the immune system. For example, it was suggested
that T-cells communicate with antigen-presenting cells (APCs) by
a unidirectional transfer of exosomal miRNA. Another example
is the transfer of miR-335 (downregulating SOX4, a progenitor
cell transcription factor), which was correlated with the transfer
of CD63 upon formation of the immune synapse (24). Further-
more, exosomes released from mature BM-derived DCs contain
more miR-125-5p, miR-146a, and miR-148, which are negative reg-
ulators of pro-inflammatory factors in myeloid cells and DCs.
Exosomes released by both immature and by mature BM-derived
DCs contain miR-34a and miR-21 (known to regulate the dif-
ferentiation of hematopoietic precursors into myeloid DCs), as
well as miR-221 and miR-222 (that prevent differentiation into
plasmacytoid DCs). Such exosomes can be taken up by recipient
DCs, and the packaged miRNAs can then be released to target
known binding sites, as shown by 3′-UTR-luciferase experiments
(46). Exosome-derived miRNAs have also been implicated in the
progression of Epstein–Barr virus (EBV) infection. Exosomes con-
taining EBV-derived miRNAs are released from infected B-cells
and taken up by DCs, where the miRNAs can then downregu-
late the expression of genes encoding immune-stimulation factors
(47). Together, these limited but suggestive data point to a role
for miRNA-based intercellular communication, mediated by exo-
somes, in the immune system, which has implications for health
and disease.
Because lncRNAs are not produced via a lncRNA-specific bio-
chemical pathway, it is not feasible to generate general or lineage-
specific lncRNA-knockout mice. The lack of evolutionary conser-
vation of lncRNAs across species further complicates the study
of their individual function. Nevertheless, several mouse knock-
outs have been generated for single lncRNAs. A landmark study
described the generation of 18 mouse strains, all with one lncRNA
deleted (48). Although the lncRNA candidates were not selected
for immune cell specificity, the study revealed key roles for several
individual lincRNAs in the viability and developmental processes
of the mice and it also highlighted the importance of using in vivo
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models to reveal the biological significance and functional diversity
of lncRNAs (48).
In the next section, we give examples of how key miRNAs play
regulatory roles in the development and activation of the immune
system and we summarize the much smaller body of evidence
implicating lncRNAs in these processes.
THE ROLE OF miRNAs IN THE DEVELOPMENT OF INNATE IMMUNE
CELLS
The innate immune system includes myeloid cells derived from
hematopoietic stem cells (HSCs) and myeloid progenitors. These
cells give rise to monocytes, which can develop into macrophages
and DCs, and to granulocytes (neutrophils, eosinophils, basophils)
through a series of developmental stages (myeloblast, promye-
locyte, myelocyte, metamyelocyte, band cell or monoblast, and
promonocyte) (Figure 4). One of the first studies of miRNA
expression in normal human granulocytes reported sets of miR-
NAs that were subject to upregulation or downregulation at dis-
crete maturation stages in neutrophil development. Although the
majority of miRNA family members showed coordinated expres-
sion patterns, the expression of some miRNAs in the same cluster
is not always synchronized. For example, the miR-17-92/oncomir-1
cluster encompasses six miRNAs (miR-17, -18a, -19a, -20a, -19b-1,
-92a-1). Among the cluster’s targets are antitumor, pro-apoptotic,
and tumor suppressor proteins. HSCs and early progenitors in
the BM express high levels of miRNAs from this cluster, whereas
their expression is reduced during myeloid and lymphoid dif-
ferentiation (49, 50). Of this cluster, miR-20a and miR-92 are
downregulated in metamyelocytes, miR-18a, miR-19a and miR-
19b are downregulated in neutrophils, while miR17-5p gradually
decreased from myeloblasts in the subsequent stages of devel-
opment (51). In miR-223 KO mice, it was shown that miR-223
deletion leads to an increase in the number of granulocyte progeni-
tors and neutrophil hyperactivity, suggesting that miR-223 acts as a
crucial regulator of granulocyte production and the inflammatory
response (52).
In vitro overexpression or knockdown experiments of miR-
29a or miR-142-3p in human leukemia cell lines showed that
the miRNA overexpression promoted monocytic and myelocytic
maturation, while blockage with antisense inhibitors promoted
not only the expression of early progenitor markers but also
reduced cell maturation, indicating these miRNAs play roles as
regulators of normal myeloid differentiation. MiR-29a and miR-
142-3p were both shown to target cyclin T2 (CCNT2), while
they were also specifically targeting the cyclin-dependent kinase
6 (CDK6) gene (miR-29a) and the transforming growth factor
β (TGFβ) activated kinase 1/MAP3K7 binding protein 2 (TAB2)
gene (miR-142-3p) (41).
An important group of miRNAs in myeloid biology is the
miR-125 family, consisting of miR-125a, -125b1, and -125b2.
The family members target crucial factors involved in HSC sur-
vival and apoptosis (42). MiR-125b overexpression, instigated by
transplanting fetal liver cells ectopically expressing miR-125b in
mice, caused a lethal myeloproliferative disorder (43). In addition,
enforced expression of miR-125b in BM chimeric mice promoted
myelopoiesis. B-cell lymphoma-2 (Bcl-2) homologous antago-
nist/killer 1 (Bak1) and the signal transducer and activator of
transcription 3 (Stat3) were proposed as possible target genes
(53). Moreover, using a miRNA-sponge approach, it was shown
that miR-125b can also regulate myelopoiesis in mice by targeting
Lin28A, an important regulator of hematopoiesis (54).
In PU.1-deficient mice, the development of macrophages, gran-
ulocytes, and B-lymphocytes is impaired, revealing that the PU.1
transcription factor is involved in myeloid and lymphoid develop-
ment (55). Several miRNAs, including the miR-17-92 cluster, are
activated by PU.1 to modulate macrophage development. In PUER
cells (murine myeloid progenitors in which macrophage develop-
ment can be supported on inducing a tamoxifen-inducible PU.1
transgene), it was demonstrated that macrophage differentiation
requires downregulation of miR-17-92 (49). Moreover, PU.1 may
also regulate macrophage development by inducing miR-146a,
miR-342, miR-338, and miR-155 (56). miR-142 is another miRNA
involved in myeloid development. In miR-142-deficient mice, a
reduction of CD4+ DCs is accompanied by a severe defect in their
ability to prime CD4+ T-cells (57). MiRNA expression profiling
during human monocyte differentiation has shown a decrease in
levels of miRNAs, the miR-17-92 cluster (miR-17-5p and miR-
20a), as well as of miR-106a (a member of miR-106a-363, a paralog
of the miR-17-92 cluster), compared to early progenitors. One of
the shared targets of miR-17-5p, miR-20a, and miR-106a is the
runt-related transcription factor 1 (RUNX-1) gene, an important
regulator of hematopoiesis (58).
Analysis of miRNA profiles in human BM precursors and neu-
trophils revealed that 135 miRNAs were differentially expressed
between the myeloid developmental stages. For instance, high
levels of miR-130a, miR-155, and miR-146a were observed in
myeloblasts and promyelocytes, followed by a decrease in expres-
sion in more mature cells. Potential targets for these miRNAs
include transcripts encoding members of the TGFβ signaling path-
way, such as TGFβ-receptor 1 (TGFβR1) and TGFβR2, SMAD2,
SMAD4, and SMAD5 (miR-130). Some miRNAs clustered with
the intermediate stages of development (miR-222, miR-200, miR
29a), while others were associated with mature neutrophils (miR-
132, miR-212). Among the predicted targets of the miRNAs
listed above are transcripts encoding cell cycle regulators, such
as CDK2 (miR-155), or proteins associated with apoptosis such as
apoptotic protease activating factor 1 (APAF1), CASP8, and Fas-
associated death domain (FADD), which are targeted by miR-132,
miR-212 (59).
Another miRNA important in the development of the innate
immune system is miR-21. It has been identified as one of the
most highly upregulated miRNAs in allergic diseases and this is
associated with high numbers of eosinophils, the main effector
cells in allergic responses. In a report by Lu et al. (60), the role
of miR-21 was evaluated in a murine ex vivo culture system. By
using RT-PCR, it was shown that during eosinophil differentia-
tion miR-21 was upregulated threefold from day 4 to day 14 in
culture. Cultures derived from miR-21−/− eosinophil progenitor
cells showed higher apoptosis than cultures from miR-21+/+ prog-
enitor cells, suggesting that miR-21 regulates the development of
eosinophils by modulating eosinophil progenitor cell growth. In
agreement with these findings, miR-21−/− mice showed reduced
blood eosinophil levels, concomitant with a reduced capacity to
produce eosinophils in the BM. Microarray analysis revealed the
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FIGURE 4 | MiRNAs and lncRNAs influence immune cell fate and function. MiRNAs and lncRNAs were shown to modulate development and function the
immune system. LncRNAs and selected miRNAs that are discussed in this review are depicted.
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differential expression of genes involved in cell proliferation, cell
cycle control, and the immune response (60).
MiRNAs INVOLVED IN INNATE IMMUNE CELL ACTIVATION
The best-known example of a miRNA involved in the activation
of innate and adaptive immune cells is miR-155. It has also been
implicated as a general and conserved feature of mouse and human
DC activation by various Toll-like receptor (TLR) ligands (61, 62).
Analyses of miR-155-deficient mice demonstrated that although
the development of DCs was unaffected, miR-155 is required for
DC maturation and the ability to promote antigen-specific T-cell
activation (61). DC maturation is also affected by miR-150, miR-
34a, and let-7i by mechanisms that involve silencing c-Fos (miR-
155), Csf1r (which controls M-CSF receptor expression; miR-34a),
and suppressor of cytokine signaling-1 (SOCS1) (let-7i) expres-
sion (61–64). Another group of miRNAs, including miR-146a,
miR-148, and miR-142, have been associated with downregulation
of inflammatory pathways and modulation of DC maturation (65–
67). MiR-146a controls DC cross-priming (by suppressing Notch1
expression and IL-12p70 production) and DC activation (by tar-
geting TLR9, TLR2, interleukin-1 receptor-associated kinase 1
(IRAK1), and tumor necrosis factor (TNF) receptor-associated
factor 6 (TRAF6) signaling) (65–68). Another important regula-
tor of DC maturation is calcium/calmodulin-dependent protein
kinase II (CaMKII), which is a target of three members of the
miR-148/152 family (miR-148a, miR-148b, and miR-152). These
miRNAs downregulate CaMKII leading to reduced expression of
MHCII, reduced cytokine production (IL-12, IL-6, TNF-α), and a
reduced antigen-presenting capacity of DCs (66).
Micro-RNA profiling of macrophages stimulated with TLR
ligands and cytokines has shown the involvement of several miR-
NAs in inflammation. After incubation of murine macrophages
with lipopolysaccharide (LPS), poly I:C, or interferon β (IFN-
β), the expression of miR-9, miR-101, miR-155 was upregu-
lated, while miR-34 and miR-27a were downregulated to mod-
ulate the levels of important regulators of inflammation. The
upregulated miRNAs target nuclear factor-κB1 (NFκB1, miR-
9), mitogen-activated protein kinase 1 (MAPK1, miR-101), and
JUN N-terminal kinase (JNK, miR-155), while the downregulated
miRNAs target NOTCH1 (miR-34a) and STAT3 (miR-27a), and
the production of pro-inflammatory cytokines such as TNF-α,
interleukin-6 (IL-6), and IL-10 (69–73).
MiR-9 was also associated with the response of polymorphonu-
clear cells (PMN) to TLR stimulation. It was interesting that out
of the 365 miRNAs tested, miR-9 was the only one upregulated
in both human macrophages and PMN after LPS activation (69).
In contrast, miR-155, miR-146a, miR-146b, miR-187, miR-125a,
miR-99b, and let-7e appeared to be macrophage-specific, while
miR-196a was PMN-specific. This underscores how some miR-
NAs are involved in the activation of multiple lineages of innate
immune cells, while others play a more lineage-specific role (69).
Recent studies have shown that microorganisms can modu-
late miRNA expression and thus the immune response during
infection, as a mechanism of immune evasion. Mycobacterium
tuberculosis induces miR-21 expression in macrophages and DCs.
It was suggested that by targeting IL-12, miR-21 modulates the Th1
immune response (74). Leishmania has also developed strategies
to subvert the host macrophage response. On Leishmania infec-
tion of human macrophages in vitro, approximately 64 out of
365 analyzed miRNAs were found to be modulated. Enrichment
analyses have revealed that several of these differentially expressed
miRNAs are involved in the regulation of TLR and pro-apoptotic
pathways (75). By using the murine model of Toxoplasma infec-
tion, an increase in the levels of the immune-miRNAs miR-146a
and miR-155 was observed in the brain of chronically infected mice
compared with non-infected controls. Further assays in miR-146
KO mice demonstrated that miR-146 ablation promotes para-
site control, resulting in long-term survival (76). MiRNA profile
expression analyses of human macrophages infected with Toxo-
plasma showed that the miR-17-92 cluster expression was signif-
icantly upregulated and that the levels of miR-17-92 were closely
related with a decrease in expression of the pro-apoptotic regula-
tor Bim. Interestingly, the Bim 3’-UTR contains predicted binding
sites for multiple miRNAs derived from the miR-17-92 family.
All the above evidence suggests miRNAs are involved in parasite
persistence and modulation of apoptosis (77).
LONG NON-CODING RNAs IN INNATE IMMUNITY
So far, most lncRNA studies have been performed in normal
cellular development or in cancer (78–82), although the role of
lncRNAs in hematopoiesis and the immune system is slowly start-
ing to emerge. The lncRNA HOTAIRM1, located antisense to
homeobox A1 (HOXA1) and HOXA2 of the HOXA gene cluster,
is expressed specifically in the myeloid lineage (83). HOTAIRM1
is upregulated during retinoic acid-driven granulocytic differen-
tiation in NB4 promyelocytic leukemia cells, which are a model
for granulocytic differentiation. Knockdown of HOTAIRM1 pre-
vents the expression of HOXA1, HOXA4, CD11b, and CD18,
but not of the more distal HOXA genes and decreased myeloid
differentiation.
The KIR antisense lncRNA was found to be expressed only
in human embryonic stem cells and other cell types with stem
cell properties (84). KIR genes encode class-I MHC receptors
expressed on human NK cells. KIR antisense lncRNA overlaps with
exons 1 and 2 of the protein-coding KIR gene, as well as with an
upstream proximal promoter region of the KIR genes. Overex-
pression of the lncRNA in NK cells was found to decrease the
expression of the KIR protein-coding gene. Wright et al. specu-
lated that the KIR genes are silenced in NK progenitors so that
they are not able to influence the process of NK cell differentiation
(84). As the KIR distal antisense promoter contains myeloid zinc
finger-1 (MZF-1)-binding sites, it is assumed that this transcrip-
tion factor regulates the expression of the KIR antisense lncRNA.
MZF-1 is a transcriptional regulator that is able to activate tran-
scription in cells of hematopoietic origins, whereas it can repress
transcription in other cell types. However, the precise mechanism
of the regulation of KIR antisense lncRNA expression is unknown.
Lnc-DC, exclusively expressed in conventional human DCs
(85), was found to induce the nuclear translocation of STAT3.
The proposed mechanism of action for this lncRNA is to prevent
SHP1 from binding to phosphorylated STAT3 and dephospho-
rylating it, thereby preventing its dimerization and translocation
to the nucleus. This is an example of a lncRNA affecting cellular
differentiation by a mechanism that takes place in the cytoplasm.
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In another study, 54 mouse pseudogene lncRNAs were found
to be induced by TNF-α (86). One of these, Lethe, functions as
a negative feedback signal that inhibits NF-κB. Its expression is
increased when TNF-α activates NF-κB, after which Lethe binds
to NF-κB and prevents it from binding to DNA, thereby inhibiting
the expression of inflammatory proteins, such as IL-6, IL-8, and
superoxide dismutase 2 (SOD2).
A whole-transcriptome profiling of mouse macrophages stim-
ulated with different TLR ligands uncovered dozens of expressed
lncRNAs (87). Activation by the synthetic bacterial lipopep-
tide Pam3CSK4, a TLR2 ligand, resulted in the expression of
62 lncRNAs. One of them, lincRNA-Cox2, acts as a key regula-
tor of the inflammatory response by mediating both activation
and repression of several immune genes. In response to TLR2-
stimulation, lincRNA-Cox2 induces the expression of hundreds of
genes, including Tlr1, Il-6, and Il-23a. LincRNA-Cox2-mediated
repression of target gene expression was found to require the
interaction of lincRNA-Cox2 with hnRNPA/B and hnRNPA2/B1,
repressing the transcription of immune cells.
Stimulation of human THP1 macrophage cells by a synthetic
lipopeptide ligand of TLR2 induced 159 lincRNAs (88). One of
these, TNFα and hnRNPL-related immunoregulatory lincRNA
(THRIL), form a complex with hnRNPL. This complex can bind
the promoter of TNFα and regulate its transcription. Microar-
ray analysis showed that THRIL is required for the expression
of various immune genes, including cytokines and other regula-
tors of TNFα expression, including IL-8, C-X-C motif chemokine
10 (CXCL10), chemokine (C-C motif) ligand 1 (CCL1), and the
colony stimulating factor 1 (CSF1). THRIL expression was also
reported to be correlated with the severity of symptoms in patients
with Kawasaki disease, an autoimmune disease mostly seen in
children.
NEAT1 (nuclear enriched abundant transcript 1) is a lncRNA
that was shown to be essential for the formation of paraspeck-
les. Paraspeckles are nuclear bodies found in mammalian cell
nuclei and it has been proposed that they play a role in sev-
eral biological processes, including cellular differentiation and the
stress response (89). It has been shown that NEAT1 is induced
by viral infection as well as by poly I:C stimulation and that,
in response to such a stimulus, NEAT1 binds to paraspeckle
protein splicing factor proline/glutamine-rich (SFPQ). This com-
plex binds to and regulates the expression of several antivi-
ral genes, including IL-8, which induces the formation of
paraspeckles (90).
THE ROLE OF miRNA IN THE DEVELOPMENT OF CELLS OF
THE ADAPTIVE IMMUNE SYSTEM
miRNAs IN T-CELL DEVELOPMENT AND ACTIVATION
Micro-RNAs have been shown to be crucial for both immune
system development and its functioning. MiRNAs that are char-
acteristically enriched in HSCs and progenitor cells are miR-125a-
5p, miR-125b-5p, miR-155, miR-130a, miR-196b, miR-99a, miR-
126-3p, miR-181c, miR-193b, miR-542-5p, and let-7e (91). Their
expression changes during immune cell development.
Some miRNAs are selectively expressed in specific stages of
immune cell development, whereas others are more broadly
expressed. Profiling studies showed that there are miRNAs, which
are preferentially upregulated in lymphocytes. The miR-181 family
is abundant expressed in developing BM B-cells and thymocytes.
The importance of miRNAs in T-cell biology has been exten-
sively studied in mice with conditional Dicer1 deletion. Con-
ditional deletion of Dicer1 in T-cell precursors using Lck-Cre
demonstrated that Dicer is necessary for the generation and sur-
vival of normal numbers of αβ T-cells (92). Cd4-Cre-mediated
deletion did not affect the viability of Cd4+ T-cells, but the num-
bers of Th1 and Th2 cells were significantly reduced, resulting from
both decreased proliferation as well as from increased apoptosis.
Dicer-deficient Cd4+ cells have been described as more prone to
differentiate into Th1 cells and Dicer-deficient cells cannot repress
Inf-γ upon Th2 stimulation (93).
Profiling of different stages of T-cell development, starting from
the double negative 1 (DN1) thymocyte stage, reveals that miRNA
profiles are similar for cells with similar developmental status (94).
DN3 and DN4 populations cluster together based on their miRNA
expression profiles, as do mature single positive Cd4+ and Cd8+
cells. DN1 cells are more similar to DN3 and DN4 cells. Neverthe-
less, expression of individual miRNAs changes depending on their
developmental stage. Each of the stages is characterized by elevated
expression of at least one miRNA or miRNA family. In DN1 cells,
miR-21, miR-29b, miR-342, miR-221, and miR-223 are elevated and
miR-16, miR-181a, and miR-15b are decreased. MiR-191 is upregu-
lated and miR-142-3p is downregulated in DN3 cells. MiR-142-5p,
miR-20a, miR-16, and miR-128b are increased, whereas miR-150
is decreased in DN4 cells. In double positive (DP) cells, expression
of miR-92, miR-181a, miR-181b, and miR-350 are enhanced, while
in Cd4+ cells, miR-669c and miR-297 are elevated. In Cd4+ and
Cd8+ cells, miR-128 is abundant.
It is interesting that, on activation of Cd4+ T-cells, Ago2
ubiquitination and consequentially its proteosomal degradation
is induced, leading to global miRNA downregulation. Moreover,
naive T-cells display reduced levels of Ago2 and differentiate more
rapidly. These findings led to the hypothesis that the decrease in
the miRNA pool on T-cell activation allows the expression of genes
regulating CD4+ T-cell differentiation and facilitates the gain of
T-cell effector functions (95). Although these are global effects on
the miRNA pool, some miRNAs can be picked out that play key
roles in T-cell biology. For example, the miR-181 family is upreg-
ulated in DP cells and its family member miR-181a decreases the
expression of Cd69, T-cell receptor α (Tcrα), and Bcl-2 (94).
Another key player is miR-125b. This miRNA is part of the
miR-99a/100~125b tricistrons, located on human chromosomes
11, 19, and 21. The tricistron on chromosome 21, encompass-
ing miR-99a/let-7c/miR-125b-2, is highly expressed in HSCs and
is responsible for maintaining stem cell properties (96). In human
naive CD4+ T-cells, miR-125b downregulates proteins that are
critically involved in T-cell differentiation: IFN-γ, IL-2RB, IL-
10RA, and PR domain zinc finger protein 1 (PRDM1, encoding
B lymphocyte-induced maturation protein-1, BLIMP-1). Overex-
pression of miR-125b inhibits the differentiation of naive T-cells
into effector cells (97). This miRNA is an example of one that
affects various stages of immune cell differentiation in different
immune cell lineages.
T-cell activation leads to highly elevated expression of miR-
155 (98). Experiments conducted on Cd4+ T-cells isolated from
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mice deficient for Bic, the primary transcript encoding miR-155,
uncovered elevated Th2 polarization, and Th2 cytokine produc-
tion (Il-4, Il-5, and Il-10) in these cells. This effect is mediated
by upregulation of c-Maf, a Th2-specific transcription factor
known to induce the expression of Il-4/5/10 (99). Th1 and Th17
responses are also regulated by miR-155. Transfection with miR-
155 promotes, whereas miR-155 inhibition decreases, the number
of Th1 and Th17 cells in mice with experimental autoimmune
encephalomyelitis (EAE) (100). Mice lacking Bic also display
decreased levels of regulatory T-cells (Tregs) in the thymus and
in the periphery while the function of these cells in vitro is not
affected. This indicates that miR-155 is required for Treg devel-
opment (101). Characteristically, miR-155 expression is induced
in Tregs by forkhead box P3 (Foxp3), while one of the main tar-
gets of miR-155 in Tregs is Socs1. When miR-155 is high, Socs1 is
low, which contributes to maintaining the competitive fitness and
proliferative potential of Tregs (102).
The miR-17-92 cluster is a master switch involved in the dif-
ferentiation into Th1 and Th17 cells. Experiments conducted in
cd4-cre-driven miR-17-92 conditional KO mice demonstrated that
Th1 development is critically controlled by miR-17 and miR-19b,
which target TgfβrII and cyclic AMP-responsive element binding
protein 1 (Creb1, miR-17 ), and Pten (miR-19b). Together, these
two miRNAs enhance T-cell proliferation and Inf-γ production,
protect from activation-induced cell death, and repress induced
Treg (iTreg) differentiation. Interestingly, miR-18a of the same
cluster antagonizes the pro-Th1 effect of miR-17 and miR-19b
through elevation of activation-induced cell death and inhibition
of proliferation (103). Subsequent experiments conducted on T-
cells isolated from conditional miR-17-92-depleted mice (that had
been retrovirally transduced with selected miRNAs from the miR-
17-92 cluster), showed that miR-17 and miR-19b were also the
miRNAs promoting Th17 differentiation. This is mediated by miR-
17 -induced downregulation of Ikaros family zinc finger 4 (Ikzf4)
and the downregulation of Pten by miR-19b (104).
Another miRNA regulating the adaptive response is miR-146a.
Profiling studies in mice showed that miR-146a expression is high
in Th1 cells and low in naive T-cells and Th2 cells (105), but
very high in Tregs (106). Level of miR-146a is also elevated in
human memory cells (both in CD4 and CD8 memory cells).
MiR-146 expression is induced on TCR stimulation and is reg-
ulated by NF-κB and the c-E26 transformation specific (c-ETS)
transcription factor. It was suggested that miR-146a exerts its
regulatory function by targeting FADD, leading to a decrease in
apoptosis. On TCR stimulation, activator protein-1 (AP-1) activ-
ity and IL-2 production are induced, but miR-146 targets both of
them, thereby enabling miR-146a to affect the duration of T-cell
activation phases (107).
As can be expected, the importance of miRNAs in CD8+ biol-
ogy has been well studied. Cd4-Cre-induced Dicer deletion in mice
leads to reduced development of peripheral Cd8+ cells due to
decreased cell survival and defective migration out of the primary
lymphoid compartment (93). As was also the case for CD4+ cells, a
decrease in Dicer (and therefore in the miRNA pool) leads to differ-
entiation, characterized by increased levels of perforin, granzymes,
and effector cytokines that are usually targeted by miR-139 (targets
Eomes and perforin) and miR-150 (targets Cd25) (108). Another
study reported that miR-15b, miR-150, miR-24, and miR-27a were
increased in Cd8+ cells (94).
MiR-155 expression also plays an important regulatory role in
CD8+ cells. It is most highly expressed in primary effector Cd8+,
shows intermediate expression in effector memory Cd8+ T-cells,
and low expression in naive Cd8+ and central memory Cd8+ cells.
Its role in the antiviral response of Cd8+ cells was demonstrated in
miR-155-deficient mice, which are characterized by an attenuated
antiviral response due to a diminished response of Cd8+ cells.
On the contrary, overexpression of miR-155 in mice enhanced the
antiviral Cd8+ response (109).
In short-lived effector CD8+ cells, miR-17-92 is upregulated
in contrast to memory cells. Experiments on mice with a con-
ditional gain or loss of miR-17-92 expression in mature Cd8+
cells after activation (controlled by the human Granzyme B pro-
moter) revealed that miR-17-92 regulates Cd8+ expansion and the
balance between effector and memory differentiation. MiR-17-92
overexpression elevates the differentiation into terminal effector
cells and concomitantly decreases the formation of polyfunctional
lymphoid memory cells. As miR-17-92 overexpression correlates
with downregulation of Pten, and in consequence induces the
PI3K (phosphoinositide 3-kinase)-Akt-mTor (mammalian target
of rapamycin) pathway, here too it was suggested that this could
be the main pathway involved in regulating cellular proliferation.
In contrast, conditional deletion of miR-17-92 leads to attenuated
proliferation of antigen-specific cells, increased Il-7Rα and Bck-2
expression, and faster acquisition of memory cell properties (110).
miRNAs IN B-CELL BIOLOGY
Experiments with conditional Dicer-KO mice in early B-cell prog-
enitors (Mb1-Cre drives deletion starting from the pro-B-cell
stage) resulted in a block in B-cell development at the transition
from pro- to pre-B-cell stage (111). Conditional deletion of Dicer-
1 in later stages of B-cell development showed that miRNAs are
also critically important for the transition from transitional B-cells
to germinal center (GC) or follicular (Fo) B-cells (112). Condi-
tional deletion of Dicer in activated B-cells [activation-induced
cytidine deaminase (Aicda-cre)] confirmed that Dicer is essential
for GC B-cell generation. The ablation of Bim partially rescued
this effect (113).
The analysis of different cell subtypes during B-cell develop-
ment in mice underscored the highly regulated, developmental
stage specific, expression of miRNAs. Hierarchical clustering of
BM and spleen B populations leads to a perfect recapitulation of
the B-cell developmental pathway. This study found the popula-
tion with the most distinct miRNA profile was that of fraction A
(FrA) B-cells, characterized by expression of miR-2138, -542-3p,
-500, -1959, -221, -1965, -1900, -1893, -501-5p, and let-7f*. FrA
cells have been reported to still retain the capacity to differen-
tiate into T-cells, while Pax5 and Cd19 expression is induced in
the next developmental stage leading to FrB/C B-cells. Among the
miRNAs not expressed in the BM are miR-150 and miR-155. These
miRNAs start to be expressed in transitional B-cells and are most
highly expressed in mature B-cells in the spleen (50).
In this B-cell lineage, specific or more broadly expressed
miRNAs also control the differentiation and activation. MiR-
126 expression decreases during B-cell maturation. Injecting
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miR-126-overexpressing HSC/progenitors cells into lethally irra-
diated mice showed that miR-126 induces the differentiation of
B-cell myeloid progenitors. One of the genes regulated by miR-126
in this process is insulin regulatory subunit-1 (Irs-1) (114).
MiR-181 is preferentially expressed in the B-cells in the BM.
Its overexpression in HSCs and progenitor cells leads to increased
levels of B-cells. Moreover, ectopic expression of miR-181 in Lin-
BM cells transplanted into sublethally irradiated mice leads to an
increase in B-cells, with a concomitant decrease of T-lymphoid
cells (115).
Mice without miR-17-92 (a Cre-deletor mouse strain with Cre
controlled by the human β-actin promoter) die shortly after birth.
Analysis of fetal liver cells from these mice showed that the fre-
quency of HSCs and the number of early progenitors was not
affected, but that the number of pre-B-cells was significantly
reduced. In miR-17-92-deficient adult mice, marginal zone (MZ),
Fo, and newly formed B-cells in spleen (as well as peritoneal
B1a and B1b cells) are reduced, whereas the relative number of
transitional B-cells was not altered. Moreover, in these mice, the
frequency of red blood cells, granulocytes, and monocytes was
also not altered (116). In contrast, another study showed that
B-cell-specific miR-17-92 overexpressing mice develop B-cell lym-
phomas due to the downregulation of negative regulators of the
PI3K pathway [Pten and PH domain and leucine-rich repeat pro-
tein phosphatase 2 (Phlpp2)] and the NF-κB pathway (Cyld, A20,
Itch, Rnfl1, and Tax1bp1), as well as due to the downregulation pro-
apoptotic protein Bim and cell cycle regulator E2F3. Together, this
results in constitutive activation of pro-survival pathways (117).
MiR-150 is expressed in mature B-cells but not in BM B-cells.
Premature overexpression of miR-150 in HSCs showed that miR-
150 blocks the generation of mature B-cells by preventing the
transition of pro-B-cells to pre-B-cells, but not the development
of T-cells, granulocytes, or macrophages. The main target involved
in this mechanism is c-Myb (118, 119).
MiR-155 controls the GC response at least partially via regu-
lation of cytokine production. Mature miR-155−/− cells isolated
from spleens are deficient in Tnf and lymphotoxin-α (Lt-α) pro-
duction (120). MiR-155 was also shown to be critically involved
in isotype switching, as reduced extrafollicular and GC responses,
and a concomitant lack of high-affinity IgG1, were observed in
the absence of miR-155 (121). MiR-155 is often overexpressed in
B-cell lymphomas including DLBCL (122), and Eµ-enhancer dri-
ven miR-155 overexpression leads to lympho-proliferative disease
followed by B-cell malignancy (123).
Finally, miR-125b appears to inhibit GC B-cell differentiation
by targeting BLIMP-1 and IFN regulatory factor 4 (IRF4); it is
essential for the post-GC plasma B-cell differentiation (124).
THE ROLE OF LONG NON-CODING RNA IN THE ADAPTIVE
IMMUNE SYSTEM
Mouse CD8+ T-cells were found to specifically express hundreds
of lncRNA genes. Many of these are specific for lymphoid cells and
their expression was dynamically changed during lymphocyte dif-
ferentiation or activation (125). A subset of 39 lncRNAs appear to
be precursor transcripts to small regulatory RNAs (miRNAs and
small interference RNAs, siRNAs), suggesting that some lncRNAs
function via smaller RNA species.
The dynamic nature and cell-specific lncRNA expression dur-
ing mouse T-cell differentiation was demonstrated by RNA-seq
analysis of 42 T-cell subsets (from early T-cell progenitors to ter-
minally differentiated T helper subsets, at multiple time points
during differentiation) (126). This led to the identification of
1,524 lincRNAs, most of which are located adjacent to key pro-
teins that regulate the immune system. Knockdown of one of these
lncRNAs, LincR-Ccr2-5’AS, led to deregulation of its neighboring
chemokine receptor genes and prevented Th2 migration into the
lung tissue (126).
In 2003, the Tmevpg1 gene was shown to control the persistence
of Theiler’s virus in the mouse central nervous system (127). Both
the mouse gene and its human ortholog, TMEVPG1/NeST, encode
a non-coding RNA located in a cluster of cytokine genes, including
the IFN-γ gene, and it was suggested to be involved in controlling
IFN-γ expression (128). Both the mouse and human lncRNAs are
expressed in Th1 cells and depend on Stat4 and T-box expressed
in T-cells (T-bet), two transcription factors regulating Th1 differ-
entiation (128). Comparison of mouse strains with and without
the capacity to clear Theiler’s virus revealed that mice that cannot
clear the infection express Tmevpg1 to a higher level, concomi-
tantly with increased IFN-γ synthesis and enhanced resistance
to Salmonella enterica infection (129). These results indicate that
lncRNA TMEVPG1/NeST regulates IFN-γ expression and plays an
important role in the susceptibility to viral and bacterial infections.
THE ROLE OF miRNAs AND lncRNAs IN AUTOIMMUNE
DISEASES
CELIAC DISEASE
Celiac disease (CeD) is characterized by a severe inflammatory
reaction to gluten peptides derived from grain storage proteins;
it occurs in patients with a susceptibility genotype. Besides shar-
ing a number of phenotypic characteristics with inflammatory
bowel disease (IBD), CeD also shares multiple genetic suscepti-
bility loci with IBD (130). So far, there are limited data on the
involvement of miRNAs in CeD and there are no publications on
the role of lncRNAs in this autoimmune disease. The lack of a suit-
able animal model for CeD makes it impossible to study the role
of specific miRNAs in vivo. However, profiling of miRNA expres-
sion in small intestinal biopsies from patients with active CeD
versus controls showed that miR-449, -492, -644, -503, -196a, -504,
-500, and -330 were differentially expressed in CeD patients, with
miR-449 as the most upregulated miRNA. Putative targets of miR-
449 include mRNAs encoding proteins involved in the NOTCH
signaling pathway. In agreement with this, the expression of the
inflammation regulator, NOTCH1, was found to be decreased in
the small intestine of CeD patients, suggesting that miRNAs can
also control inflammation in CeD (131). Indirect evidence for the
involvement of particular miRNAs in CeD was found by analyz-
ing genome-wide association study (GWAS) data. Kumar et al.
have described how CeD-associated SNPs may actually affect the
3′-UTR of IRF4, PTPRK, and ICOSLG and suggested that these
might change miRNA-binding sites (132).
INFLAMMATORY BOWEL DISEASE
Inflammatory bowel disease includes Crohn’s disease (CD) and
ulcerative colitis (UC) (133). Recent GWAS and meta-analyses
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have identified 163 common risk loci for IBD and 47 unique
risk loci associated with UC (134). Although the cause of IBD is
unknown, there is evidence to suggest that an abnormal immune
response to intestinal flora leads to this disease in genetically sus-
ceptible individuals. There have been various miRNA profiling
studies published on IBD and the miRNA profiles in tissues or
serum of UC and CD patients at different stages underscore the
importance of miRNA as key regulators of the immune response
in this disease (130, 131). Circulating miRNAs in serum were sug-
gested as useful biomarkers for CD diagnosis. MiRNA RT-PCR
revealed a set of 11 miRNAs that were significantly elevated in
CD patients, but not in the serum of controls or in the serum of
patients with active CeD (135).
The first report of miRNA expression in colonic mucosa
samples from IBD patients identified 11 miRNA differentially
expressed in active UC patients versus controls (136). Since then,
the number of miRNAs linked with IBD has increased gradually
(137). Several reports have demonstrated the alterations in expres-
sion of miRNAs involved in modulating different aspects of the
innate and adaptive immunity, such as miR-21, miR-29a, miR-150,
and miR-155 (136, 138, 139). Recently, by using microarray-based
miRNA profiling of colonic mucosal biopsies, five miRNAs were
shown to be upregulated in patients with active UC compared to
quiescent UC, CD patients, and controls. In addition, expression
of two miRNAs, miR-125b-1 and let-7e*, was enhanced in patients
with quiescent UC compared with active UC, CD patients, and
controls, supporting the utility of miRNAs as biomarkers to dis-
tinguish the different IBD stages (140). An interesting point is
that SNP rs2910164, which has been associated with susceptibil-
ity to CD, has also been linked to miR-146a (141). Subsequent
reports have identified other miRNAs that may affect the control
of inflammation during IBD. MiRNA-155, which has been asso-
ciated with T-cell, B-cell, and innate cell function, was detected
in the blood of CD and UC patients, but not in that of healthy
controls (142). RT-PCR has revealed an upregulation in miR-21
levels in mucosal tissue and serum and UC patients (143). Further,
in vitro analyses demonstrated that overexpression of miR-21 in
mucosa from UC patients and in the Caco-2 cell model resulted in
impaired tight junction formation and decreased barrier function,
suggesting a pathogenic role for miR-21 in UC (143). Using the
murine model of dextran sulfate sodium (DSS)-induced colitis, it
was found that overexpression of miR-146b (by expression vec-
tor) or ablation of miR-21 (miR-21 KO mice) reduces intestinal
inflammation and restores epithelial barrier function by activat-
ing NF-κB (miR-146b) or by negatively regulating RhoB (miR- 21)
(144, 145).
The involvement of other inflammatory pathways and
processes regulated by miRNAs was also proven to be important
in IBD pathogenesis. Several studies have shown that the pattern
recognition receptor NOD 2 is upregulated by miR-146 or down-
regulated by miR-122, while the colonic leukocytic trafficking is
regulated by miR-141 (146–148).
More studies have led to an understanding of the role of miR-
NAs on carcinogenesis, since IBD has been well established to
be a predisposing condition for colorectal carcinoma (CRC). For
instance, the levels of miR-143 and miR-145 were downregulated in
UC patients compared with normal controls. Among the putative
targets of these miRNAs are proteins associated with cell cycle reg-
ulation, such as K-RAS,API5, MAPK kinase-2 (MEK-2), and IRS-1
(149). A recent study identified miR-224 as one of the most upreg-
ulated miRNAs during the transition from IBD to IBD-associated
CRC. In silico analysis and functional assays confirmed that miR-
224 targets the cell cycle regulator p21, which could suggest the
involvement of miR-224 in IBD-associated carcinogenesis (150).
Other studies have demonstrated a dysregulation of miR-21 and
miR-155 during active IBD in IBD-dysplastic lesions (151, 152).
In conclusion, these inflammation-related miRNAs target
important regulators of carcinogenesis, such as programed cell
death 4 and mismatch repair elements, which could provide a
biochemical link from IBD to cancer development (151, 152).
Because of their specific expression profiles, miRNAs are
considered useful biomarkers for IBD diagnosis and as predic-
tors of disease progression (153). MiR-122, miR-17, and let-7e
were found to be altered during the progression of IBD (147),
while a set of studies on immune-mediated diseases (including
IBD) highlighted miRNAs as promising indicators of response to
immunosuppressor treatment (20).
However, the role of lncRNA in the pathogenesis of CD remains
elusive. A GWAS study identified leucine-rich repeat kinase-2
(LLRK2), which is part of a complex including the large non-
coding RNA repressor of NFAT, as associated with CD. In line
with this, when wild-type mice were sublethally irradiated and
reconstituted with Lrrk2-deficient hematopoietic cells, they were
more susceptible to DSS-induced colitis. This suggests that LLRK2
deficiency increases UC severity (154). In addition, high levels of
lncRNA DQ786243 were found in the blood of patients with CD.
Subsequent overexpression of DQ786243 in Jurkat cells showed
a correlation between the lncRNA and the expression of the
Foxp3 regulator, CREB, suggesting that DQ786243 is involved in
inflammation control and CD pathogenesis (155).
MULTIPLE SCLEROSIS
Multiple sclerosis (MS) is an autoimmune, demyelinating neu-
rodegenerative disorder, mostly affecting adults. Most often, the
disease first manifests itself as relapsing-remitting MS (RR-MS),
which typically progresses into secondary progressive MS (SP-
MS) after 10–25 years. It is thought that RR-MS is more pro-
inflammatory in nature, while SP-MS is mostly associated with
neurodegeneration,although there is a small percentage of patients
who present with neurodegenerative symptoms, without any evi-
dence for former pro-inflammatory episodes. They have an aggres-
sive form of MS called primary-progressive MS (PP-MS) (156).
Multiple studies suggest the involvement of miRNAs in MS and
changes in miRNAs have been detected in circulation, in brain tis-
sue, in immune cells, and in CSF. Several miRNAs associated with
the immune response have also been linked with MS, including
miRNAs regulating the Th1 response, such as miR-155 (100) and
miR-29 (157), but also Th17-associated miRNAs [miR-155 (100),
miR-17-92 (104), miR-132 (158), and miR-326 (159)]. Of inter-
est is that the level of miR-326 in peripheral blood lymphocytes
was suggested to distinguish between the relapsing and remitting
phases of MS (160).
One of the miRNAs important in MS pathology is miR-155,
the expression of which is elevated in RR-MS patients during
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relapse, as well as in the murine EAE model. In EAE mice, deliv-
ery of miR-155 stimulates the development of inflammatory Th17
and Th1 cells, whereas applying miR-155 inhibitors reduces these
processes (100).
The immune response in MS in the brain may be also regulated
indirectly by changes in the blood–brain barrier (BBB) perme-
ability. Elevated levels of miR-155 in the neurovascular part of
the brain of MS patients as well as in EAE mice are linked with
a decreased function of the BBB. The potential targets of miR-
155 suggested to be involved in BBB function are focal adhesion
proteins (DOCK-1, dedicator of cytokinesis-1, and Syntenin-1)
and proteins involved in cell–cell interaction (Annexin-2 and
Claudin-1) (161).
Another miRNA that plays a crucial role in regulating the func-
tion of the BBB, and consequently in regulating the immune cell
influx in the brain, is miR-125a-5p. Overexpression of this miRNA
elevates barrier tightness, with thicker and more continuous tight
junctions formed by vascular endothelial-cadherin (VE-cadherin)
and zona-occludens-1 (162).
MiR-92a-1* is reported to be increased specifically in the
plasma of RR-MS patients compared to healthy controls or SP-MS
patients. Furthermore, its level correlates negatively with disease
duration and disability score. Elevated levels of miR-92 can also
distinguish RR-MS from another neuronal disease, amyotrophic
lateral sclerosis. Using ingenuity pathway analysis (IPA), it was
predicted that miR-92 affects CD40 signaling by targeting CD40
directly (163).
Let-7a expression is diminished in SP-MS patients compared
to healthy controls. IPA analysis led to the suggestion that let-7a
targets TLR4 and TLR9, as well as IL-12RB2 and TGF-βR1 (163).
Let-7a also regulates neuronal differentiation (164).
MiR-145 appears to decrease during the transition from RR-MS
to SP-MS and is negatively correlated with disability score (163).
This miRNA is known to regulate insulin-like growth factor 1
(IGF-1) signaling (IGF-1R, IRS1, and IRS2) (165).
Long non-coding RNAs have been shown to be involved in
the development of neurodegenerative disorders, like β-secretase-
1 (BACE1)-AS, the brain cytoplasmic RNA (BC200 RNA) in
Alzheimer’s disease, and the brain-derived neurothrophic factor
(BDNF)-AS in Huntington’s disease (166). BACE1-AS elevates
the protein level of BACE1, an enzyme involved in generating
β-amyloid, by binding and stabilizing BACE1 mRNA (167). The
level of BC200 RNA is elevated in the brains of Alzheimer’s patients
(168) and this lncRNA was shown to interact with proteins partic-
ipating in mRNA transport in neurons (166). BDNF-AS inhibits
the expression of BDNF, a growth factor promoting neuron mat-
uration and survival (169, 170). It is not yet known whether these
lncRNAs are also involved in MS.
Impaired remyelination and neuron apoptosis are two hall-
marks of the neurodegenerative phase of SP-MS. Interestingly,
the level of the small non-coding RNA 715 (sncRNA715), which
inhibits oligodendrogial myelin basic protein (MBP) translation,
is elevated in demyelinated chronic lesions in MS patients (171).
In contrast, remyelination can be affected by exosomes released
by DCs. Stimulating DCs with low levels of INF-γ causes the
release of exosomes enriched in miRNA involved in the regu-
lation of myelin production (miR-219) and anti-inflammatory
response (miR-181a, -451, -532-5p, and -665) compared to exo-
somes released from unstimulated DCs. This, in turn, increases
myelination and reduces oxidative stress in hippocampal slice cul-
tures. Moreover, intranasal delivery of these exosomes elevates the
central nervous system myelination in vivo (172). LncRNAs have
also been implicated in the regulation of apoptosis, and because
neuron apoptosis is important in MS, the role of lncRNA in
apoptosis in MS should be investigated further (173).
Two MS SNPs are associated with miRNA genes (miR-223;
rs1044165 and miR-23; rs3745453) and the expression of these
miRNAs was investigated in MS patients (174). MiR-223 is
important for the innate immune system, e.g., affecting the
non-canonical NF-κB pathway during macrophage differentiation
(175), whereas miR-23a promotes myelination by elevating oligo-
dendrocyte differentiation and myelin synthesis (176). Both miR-
223 and miR-23a are decreased in serum from RR-MS patients.
However, the expression of miR-233 is increased in peripheral
blood mononuclear cells (PBMCs) from both RR-MS as well as PP-
MS patients, whereas miRNA-23a is upregulated only in PBMCs
from RR-MS patients (174). Thus far, no eQTL-effect of both SNPs
on the respective miRNAs has been found.
Another study predicted that SNP rs28366, which is in mod-
erate linkage disequilibrium (r2= 0.4) with MS risk variant
rs17066096, might affect the binding of miR-2278 and miR-411-
5p- to the 3′-UTR of IL22RA2. However, although these miRNAs
did indeed bind to the 3′-UTR in an in vitro assay, the SNP did not
affect the binding (177).
PERSPECTIVES
Integration of autoimmune disease-associated SNPs with data on
the functional regions in the genome shows that ~90% of these
SNPs intersect with regulatory regions in the DNA (enhancers,
promoters) rather than with protein-coding regions (exons) (29,
130). Autoimmune disease-associated loci often encompass genes
known to play critical roles in immunological diseases. In these
common illnesses, characteristically dozens of disease-associated
SNPs have been identified, each predisposing moderately to dis-
ease. The general consensus for these immune-related diseases is
that many SNPs with modest effects converge on a limited num-
ber of biological pathways and it is the sum of these effects that
influences the phenotype to a large extent.
In the last two decades, thousands of regulatory RNA genes have
been identified that also regulate gene expression. In fact, the total
number of known miRNA genes plus lncRNA genes is now more
than 15,000 and this is starting to approach the number of known
protein-coding genes (~22,000). There is convincing evidence that
autoimmune SNPs also affect miRNA and lncRNA biology. SNPs
have been identified that locate to miRNA-binding sites and some
SNPs appear to regulate the expression of lncRNAs (32, 132, 174,
177). This means that to fully understand the changes to tran-
scriptional programs that contribute to disease, we need to take
into account multiple gene-regulatory pathways, involving classi-
cal transcription factors, miRNAs, and lncRNAs. This situation is
further complicated by the fact that these pathways, and the mol-
ecules involved in them, not only regulate other molecules within
their own class, but also molecules of other classes. In the case of
miRNAs and lncRNAs, for instance, it has already been reported
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that lncRNAs can be targeted by miRNAs, that lncRNAs can encode
miRNAs, that lncRNAs and miRNAs can compete for targets, and
that some lncRNAs can function as miRNA sponges (178).
With advances in next generation sequencing technology and
the anticipated reduction in the cost of using these techniques,
many more regulatory RNAs (and perhaps even novel classes of
regulatory RNAs) are likely to be discovered. If we focus on dis-
covering novel miRNAs and lncRNAs, we should take into account
that the expression of both classes of regulatory RNAs is more
cell-type- and stimulus-dependent than the expression of protein-
coding genes. This has two consequences: (1) for regulatory RNAs
affecting other RNA species, both the regulator and the target need
to be expressed in the same cell type and (2) to better understand
the molecular basis of human disease, it means that the tissues that
specifically contribute to a disease need to be identified, isolated,
and profiled. Subsequently, the targets of the known and novel
regulatory RNAs need to be identified; this is currently a major
challenge. It is known that miRNAs can bind dozens of targets and
that single mRNAs can be regulated by multiple miRNAs. Canon-
ical miRNA action is based on complementarity between the seed
sequence of the miRNA and a binding sequence in the 3′-UTR
of its target. This “rule” has been used to design algorithms that
predict miRNA-binding sites in the 3′-UTRs of target mRNAs [see
review by Hrdlickova et al. (18) for listing of web-based tools]. The
field of lncRNA research is quite new and the functions of lncRNAs
are still poorly understood. Although characteristics such as cell-
type specificity and their role in epigenetic regulation also make
lncRNAs interesting therapeutic targets, much more basic research
is required to fully understand and appreciate the potential impor-
tance of lncRNAs in diagnostic work and treatment. There are
currently no target prediction algorithms for lncRNAs, primarily
because lncRNAs represent a heterogeneous group of regulatory
RNAs that exhibit many different mechanisms of action. More-
over, their interaction with specific targets, which can be DNA or
protein, appears to be determined by their structure rather than by
their sequence. A factor that complicates lncRNA research is that
they exhibit little sequence conservation throughout evolution.
It is, therefore, not easy to identify mouse homologs of human
lncRNAs for instance. However, it is possible that functional struc-
tures – independent of sequence – are more conserved, but there
is not yet enough data available to prove definitely that this is
a general feature. In contrast, miRNAs and their targets are well
conserved throughout evolution, which makes it relatively easy to
extrapolate mouse miRNA results to the human system.
Importantly, in silico predictions of targets and functions for
regulatory RNAs need to be followed up by in vitro validation.
Recently, advanced assays have been developed based on cross-
linking of regulatory RNAs to their targets followed by analysis of
their binding partners. By using such assays, miRNA targets can
be identified by RNA sequencing [e.g., (179)] and lncRNA inter-
acting partners can be determined by DNA sequencing or mass
spectrometry [e.g., (180)]. These technically challenging assays
are currently considered to be the state-of-the-art in pinpointing
the targets of regulatory RNAs.
Much attention in the miRNA field is currently focused on
the potential of using circulating miRNAs as biomarkers for dis-
ease. Tissue-specific expression profiles of miRNAs and lncRNAs
are one of the features that make them attractive biomarker candi-
dates. MiRNAs are of particular interest because it has been shown
that they exhibit stability in plasma and serum, a feature that is not
expected of lncRNAs. MiRNA (and lncRNA) levels can be mea-
sured by PCR, array technology, or by next generation sequencing
applications, with each technique having its own advantages and
disadvantages (181). Unfortunately, there are no simple tests (for
instance dip-sticks) available to detect RNAs. Additionally, miR-
NAs are attractive targets for therapy. For instance, decoys can be
applied to prevent miRNAs or lncRNAs from binding to their tar-
gets. Miravirsen, an inhibitor of miR-122, was shown to reduce
HCV viremia in monkeys and is currently the most advanced
miRNA-based drug in the clinical testing pipeline (Phase II). For
more details on the potential of miRNAs or lncRNAs in the clinic
and on the challenges associated with their delivery to target tis-
sues, we recommend the reviews by Ling et al (182) and Li and
Rana (183). It is clear, however, that the elucidation of more com-
plete transcriptional networks, containing regulatory RNAs and
protein-coding genes, will soon provide several more potential
targets for therapeutic options.
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